Democratic lawmakers are seeking answers from the White House regarding the special access granted to certain individuals for Eli Lilly’s experimental obesity drug.
This unusual access has not only raised eyebrows among politicians but has also captured significant public interest.
As discussions unfold, the implications of such access on equity and transparency in drug availability are becoming increasingly relevant.